The Claim

Five clinical studies involving 630 human participants have investigated the use of GLP-1 receptor agonists—specifically Exenatide in three trials and Dulaglutide in two—for substance use disorders, representing limited but emerging evidence in humans.

Source: Potential role of glucagon-like peptide-1 (GLP-1) receptor agonists in substance use disorder: A systematic review of randomized trials.

What the research says

Supports is higher

Support is ahead, but a single strong opposing study can change this.

Supports
20score
Challenges
0score

These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.

Description
1 study reviewed
In plain English

A few small studies have tested diabetes drugs like Exenatide and Dulaglutide in people with addiction, and while there’s not much data yet, it’s an area scientists are starting to explore.

See the scientific wording

A small number of clinical studies (n=5) involving 630 participants have evaluated GLP-1 receptor agonists for substance use disorders, using Exenatide in three trials and Dulaglutide in two, representing limited but emerging human evidence in this area.

What the research says

1 study

  1. Study: Potential role of glucagon-like peptide-1 (GLP-1) receptor agonists in substance use disorder: A systematic review of randomized trials.

    The study looked at the same drugs and number of people mentioned in the claim and found early signs they might help with addiction, which supports the idea that this is a new but growing area of research.

Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies

Fit Body Science verdict — we translate health claims into clear verdicts backed by peer-reviewed research.

Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.